Clomid Disease Interactions

The use of clomiphene is contraindicated in patients with undiagnosed, abnormal genital bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present.

The use of clomiphene is contraindicated in patients with liver disease or history of hepatic dysfunction.. Clomiphene undergoes enterohepatic circulation and is metabolized by the liver. The serum concentration of clomiphene may be increased and the half-life prolonged in patients with compromised hepatic function.

The use of clomiphene is contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or an organic intracranial lesion such as a pituitary tumor. Clomiphene interacts with estrogen receptors in various tissues, including the pituitary, the response of which is an increase in the release of pituitary gonadotropins.

The use of clomiphene is contraindicated in patients with uncontrolled adrenal function. Alterations of adrenal function can impede pregnancy. Clomiphene therapy can result in alteration in steroid synthesis and/or fluid regulation.

Cases of hypertriglyceridemia have been reported in patients receiving clomiphene treatment. Preexisting or family history of hyperlipidemia and use of higher than recommended dose and/or longer duration of treatment with clomiphene citrate are associated with a risk of hypertriglyceridemia. Periodic monitoring of plasma triglycerides is recommended in patients with preexisting or family history of hyperlipidemia. Pretreatment screening of triglyceride levels is recommended in patients initiating clomiphene citrate therapy.